Arca Biopharma (ABIO) has released an update to notify the public and investors about its officers.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
On January 30, 2024, ARCA biopharma, Inc.’s Board approved compensation for its non-employee directors under its Director Compensation Policy. Each director received options to purchase 6,000 shares at $1.64 per share, in line with the closing price on the Nasdaq on that day. These options, governed by the ARCA 2020 Equity Incentive Plan and standard agreements, will vest monthly over a year provided the directors continue their board service.
For further insights into ABIO corporate activity, check out TipRanks’ Insiders Trading Activity page.
For a comprehensive understanding of the announcement, you can read the full document here.